New Study Reveals How Age and Biological Sex Shape Cancer Immunity and Treatment Response

A new study published in Nature Aging investigates how biological sex and the aging process influence the immune system’s ability to fight cancer. Led by researchers at the Mass General Brigham Cancer Institute, the research combines experimental mouse models with human datasets to shed light on why anticancer immunity declines over time and how these changes differ between biological males and females.

As people age, immune function naturally diminishes, making it more difficult for the body to ward off infections and malignancies. This gradual decline presents a significant hurdle for cancer immunotherapies, such as immune checkpoint blockade, which depend heavily on a patient’s immune system to detect and react to tumor antigens. Despite the recognized differences in cancer incidence, immune responses, and treatment outcomes between biological men and women, the underlying mechanisms linking biological sex to immune aging have remained largely elusive.

Tracking T Cell Immunity Across the Lifespan

To better understand these dynamics, the investigators focused on T cell immunity, immune surveillance, and tumor antigen recognition. Using experimental mouse models of melanoma alongside public data from human melanoma patients, the research team tracked physiological shifts in lymph nodes, the thymus—the immune organ responsible for T cell maturation—and naive CD8 T cells across the lifespan.

Naive CD8 T cells are newly generated immune cells that have not yet encountered an active threat. The investigators monitored how alterations in these cells impacted the recognition and management of melanoma tumors. Furthermore, they utilized human imaging and immune-cell datasets to confirm whether comparable age- and sex-associated patterns manifest in humans.

Lead author Lutz Menzel, Ph.D., formerly of the Department of Radiation Oncology within the Mass General Brigham Cancer Institute, and senior author Tim Padera, Ph.D., along with their colleagues, also manipulated how naive T cells developed into specialized immune cells in their animal models to pinpoint the drivers behind observed variances. They additionally tested short-term regeneration of thymic function to see if anticancer immunity could be bolstered in aging subjects.

Earlier T Cell Losses Observed in Males

The investigations revealed notable divergences in how the immune system ages in biological male and female subjects. Specifically, male mice experienced an earlier loss of naive CD8 T cells in life, which coincided with an earlier reduction in lymph node size. Consequently, fewer local T cells remained available to identify tumor antigens, leading to compromised anticancer immune responses.

However, the researchers discovered that temporarily dampening the suppressive influence of male sex hormones on the thymus in middle-aged male mice successfully replenished naive CD8 T cells within the lymph nodes. This intervention restored tumor recognition capabilities and enhanced the therapeutic efficacy of immune checkpoint blockade. Human clinical data reinforced key elements of this sex-biased immune aging pattern, including parallel variations in lymph node size, age-related thymic shrinkage, and naive CD8 T cell populations.

Reevaluating the Role of the Adult Thymus

These findings offer a clear mechanistic link between thymic function and the immune system’s capacity to recognize malignant cells. Historically, medical understanding viewed the thymus as an organ that becomes largely irrelevant after childhood. However, recent investigations from Mass General Brigham laboratories have challenged that perspective, demonstrating that adult thymic health correlates with overall health status and success rates in cancer immunotherapy.

The new study builds on this shift by illustrating how ongoing thymic output sustains the pool of naive T cells residing in lymph nodes, ensuring they are available to detect cancer antigens. Understanding these age- and sex-dependent immune environments could eventually empower clinicians to evaluate an individual patient’s capacity to mount novel anticancer immune responses, ultimately guiding more personalized treatment decisions.

Key Findings at a Glance

• Male mice demonstrated earlier lymph node contraction and naive CD8 T cell depletion compared to females.
• Temporarily reducing androgen suppression on the thymus restored naive T cells and improved checkpoint blockade responses in middle-aged male mice.
• Human datasets corroborated these age- and sex-related patterns of immune system aging.
• The study highlights the adult thymus as a crucial player in maintaining lifelong immune competence and a potential target for future cancer therapies.

Source: Medical Xpress